Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

As global shortages hit Ozempic and Wegovy, rivals like Eli Lilly gain ground, including in India’s growing market for ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley ...

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk (NYSE: NVO) ...

Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.

"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide ...